❌

Visualização de leitura

How a blue wave crushed the tech right

Elon Musk

Kent NISHIMURA / AFP via Getty Images; Rebecca Zisser/BI

  • Elon Musk spent $446 million on the midterm elections. He ended up one of the biggest losers.
  • Democrats tapped into voter fury over data centers encroaching on their neighborhoods.
  • Markets are confident in Big Tech stocks, but CEOs may now have to face Congressional subpoenas.

Trump's presidential term doesn't end for another two years. But the political sea change against tech titans like Elon Musk starts now.

For Musk, the $446 million he spent to elect Republicans in the midterms wasn't much. It amounted to about a twentieth of a percent of his net worth.

In the world of politics, it seemed like a tsunami. Ultimately, Musk was the one drowned by a wave.

The blue wave that swept America on election night was a repudiation of President Donald Trump's policies, including tariffs and a war in Iran that fueled inflation. It was a backlash against data centers, the physical symbols of how artificial intelligence has been taking over the world. And it was a rebuke to Silicon Valley elites and their vision for the future.

Shares of Musk's SpaceX and Tesla were down 5% and 2% in Wednesday trading, respectively, after Texas voters pushed out longtime Republican governor Greg Abbott and elected Democratic candidate James Talarico for the US Senate.

"Data centers in space looking pretty appealing right now," Musk wrote on X.

An AI reckoning is here

The market Wednesday showed that it still has confidence in many Big Tech companies, including Microsoft, Amazon, and Google parent Alphabet. Share prices slipped for chip makers Nvidia and TSMC. Worse off were Neocloud companies, which provide cloud computing services for AI customers. CoreWeave shares fell 9% Wednesday, while Nebius Group fell more than 6%.

It isn't all bad news for tech billionaires. In California, they appear likely to defeat a billionaire wealth tax, the prospect of which had led Google cofounders Larry Page and Sergey Brin to leave the state. Voters may even pass a competing measure pushed by Gov. Gavin Newsom that would ban future wealth taxes.

It has been two years since Big Tech bent the knee to Trump after he won the 2024 presidential election. Tech's biggest players had made a big bet on artificial intelligence, and they needed a friend in the White House. Meta CEO Mark Zuckerberg, Amazon, and others donated to his inaugural fund. Big Tech companies also put millions toward Trump's White House ballroom project.

Mark Zuckerberg, Lauren Sanchez, Jeff Bezos, Sundar Pichai and Elon Musk attend the Inauguration of Donald J. Trump, January 2025
Tech executives including Mark Zuckerberg, Jeff Bezos, Sundar Pichai, and Elon Musk attended Trump's 2025 inauguration.

Julia Demaree Nikhinson - Pool/Getty Images

Tech giants since then have been spending mind-boggling sums of money to build data centers. They sparked anger among voters concerned that mammoth projects would drive up their electricity bills, guzzle water, and create air and noise pollution. Nationwide, data centers have decreased neighbors' water pressure, strained electric grid systems, and increased reliance on heavily polluting fossil fuels, such as natural gas or coal.

NBC News' exit poll Tuesday found that 76% of voters would oppose the construction of a new data center in their community; 56% said AI and data centers were a crucial or major factor in their vote for Congress.

In more than 50 local ballot measures, voters had the chance to express their displeasure toward data center construction. Results haven't been tallied for all of those elections, but the early results are clear: More than 30 measures restricting data centers passed, many of them in Ohio, home to a key data center for OpenAI's $500 billion Stargate project. Gina Hinojosa, Texas's Democratic governor-elect, has pledged to impose an immediate moratorium on building new data centers in the state. League City, a town outside Houston, also voted for a ballot measure rejecting Flock license-plate reader cameras, which many consider an intrusive form of surveillance.

Democrats tapped into voter fears that AI could wipe out jobs — or all of humanity. When they take over Congress, they could force a reckoning for Big Tech's no-holds-barred AI acceleration. Democrats will now be able to subpoena tech executives and require them to testify on Capitol Hill. Sen. Ed Markey, a Democrat from Massachusetts, wrote on X that tech executives "are going to need to plant new forests for all of the subpoenas we'll be printing."

At the same time, Big Tech leaders may be able to use the increased oversight as an excuse if they don't deliver on the sky-high valuations and ambitious promises they have made to investors.

Don't mess with Texas

Musk moved Tesla's corporate headquarters to Austin in 2021. Tesla and SpaceX both then reincorporated in Texas in 2024. Musk said he moved the companies to the Lone Star State for more favorable tax, land acquisition, and corporate legal policies.

Tesla now has a large manufacturing facility outside Austin, Texas, and the company's robotaxi service operates in multiple cities across the state. SpaceX, meanwhile, launches its Starship rocket from its Starbase facility in Boca Chica, near the Mexican border.

Much of Musk's political donations this year went toward supporting Ken Paxton, the powerful but controversial longtime Texas state attorney general running for US Senate. The state hadn't elected a Democrat statewide since 1988. Trump won the state in 2024 by 14 points. Paxton seemed like a safe bet.

Instead, Democrat James Talarico, a state representative from Austin who put criticism of billionaires controlling politics at the center of his campaign, trounced Paxton by 12 points. More shockingly, Abbott, who ran for reelection as governor, lost to a Democratic candidate who a year ago was an obscure state legislator.

U.S. Sen.-elect James Talarico (D-TX) speaks during a midterm election night event
Democrat James Talarico, a state representative from Austin, put criticism of billionaires controlling politics at the center of his campaign.

Chip Somodevilla/Getty Images

Dan Ives, the founder of research firm Yorkville Ives who is bullish on SpaceX and Tesla, said in a Wednesday note that Musk "needs to find the path forward with Texas now with a Democratic win on both the Senate and Governor race."

Musk had clashed with Talarico, who, in his acceptance speech, singled out the richest man in the world and likened his win to the story of David and Goliath.

"We just proved that all the money in the world is no match for the people of Texas," Talarico said.

Musk reacted on X to the Democratic sweep.

"Guess my election-interfering space lasers didn't work this time," he wrote.

Ben Shimkus contributed to this story.

Read the original article on Business Insider
  •  

Satellite images reveal trouble brewing at Microsoft's AI data center partners

Microsoft's Amy Hood speaks at the annual Microsoft shareholders meeting in 2016.
Microsoft chief financial officer Amy Hood.

Elaine Thompson/AP

  • Microsoft said third-party data center delays contributed to a shortfall in infrastructure spend.
  • Satellite imagery points to potential setbacks for the massive IREN and Nebius data center projects.
  • Neoclouds are under mounting pressure to deliver on their multibillion-dollar promises.

Microsoft spent $5 billion less than expected on AI last quarter, and satellite images may show why.

In Microsoft's quarterly earnings call last month, chief financial officer Amy Hood said delays by third-party cloud providers contributed to lower-than-expected AI infrastructure spending. Microsoft cut its annual capital expenditure forecast by $5 billion.

The news sent neocloud stocks tumbling, highlighting concerns that the young companies can't deliver on their multibillion-dollar promises.

Although Microsoft didn't name names, two data center projects from neoclouds Iren and Nebius could be responsible, according to satellite analysis from research firm Aterio.

In Texas, IREN is building four data centers under a $9.7 billion deal with Microsoft. An October 21 satellite flyover found that one of the buildings, Horizon 4, was still missing backup power generators and cooling equipment — and risked missing its scheduled delivery by the end of the year, Aterio said.

IREN previously said that equipment shortages had delayed the first building, Horizon 1, which Microsoft accepted in August.

Data center operator DataOne is developing the second project in New Jersey for Nebius under a $17.4 billion deal with Microsoft. Aterio said roughly 140 megawatts of that project's planned capacity could slip into 2027.

It struggled to get permits for its original power generators, then faced more approval delays after switching to fuel cells, said Aterio data analyst Daud Shiraz. Regulators fined DataOne $1 million in September for operating generators without the required permits.

The potential delays point to broader struggles. In October, Microsoft axed a deal with another neocloud, Nscale, due to power-supply delays.

The research firm Currence estimates that 30% to 50% of planned data center capacity initially scheduled to come online this year could be pushed into 2027 or later due to electricity shortages and other construction issues.

A Microsoft spokesperson said its "approach to infrastructure is built on flexibility and optionality," combining its own data centers with leased facilities and third-party providers.

IREN and DataOne declined to comment for this story. Nebius did not respond to a request for comment from Business Insider.

Have a tip? Contact this reporter via email at gweiss@businessinsider.com or Signal at @geoffweiss.25. Use a personal email address, a non-work WiFi network, and a non-work device; here's our guide to sharing information securely.

Read the original article on Business Insider
  •  

The feds made $627 million selling Anthropic stock from SBF's friends — but could have made billions

sam bankman-fried sdny
Sam Bankman-Fried and two of his co-conspirators held investments in Anthropic, the AI company that has since soared in value.

Bloomberg/Getty Images

  • The feds seized Anthropic shares last year from Sam Bankman-Fried's associates.
  • Several months later, the government sold them for $627 million.
  • If Anthropic IPO'd in November at $1.5 trillion, those shares would be worth nearly $4 billion.

Last year, the federal government made a windfall of $627 million when it sold Anthropic shares it had seized from associates of crypto fraudster Sam Bankman-Fried.

If it had held on to that stake, its windfall could have been a lot bigger.

The federal government last year sold shares of Anthropic that had belonged to Caroline Ellison and Nishad Singh, two co-conspirators in the FTX fraud case. The proceeds went to compensate victims of the fraud, a Justice Department spokesperson told Business Insider.

Anthropic's S-1 filing on Monday revealed how much the federal government made from the sale of those shares. The prospectus doesn't name Ellison and Singh specifically. It says the government in October 2025 sold 4,453,900 Series B shares of Anthropic that "had been forfeited by former holders in legal proceedings to which we were not a party."

The figure matches up exactly with the combined $50 million in shares that Singh and Ellison purchased for $11.2261 each in Anthropic's 2022 fundraising round, and later forfeited to the government.

The shares represent about a quarter of a percent of Anthropic today. But given the company's explosive growth, they are still worth a fortune.

Anthropic hasn't yet announced the stock price for its expected November initial public offering. At a $1.5 trillion valuation, the shares would be worth a total of about $3.94 billion. That would be six times as much as the government sold the shares for a year ago.

"One of the Justice Department's top priorities is returning forfeited funds to victims through the asset forfeiture program whenever the law allows," the DOJ spokesperson said.

The feds' stake in Anthropic

How the federal government came to own a chunk of Anthropic in the first place is a story involving a notorious fraudster and a complicated criminal forfeiture process.

Bankman-Fried participated in Anthropic's 2022 Series B fundraising round with Singh and Ellison. Singh purchased $40 million of the Series B shares, and Ellison acquired $10 million.

Singh and Ellison later pleaded guilty to crimes related to their work with Bankman-Fried and testified against him at his Manhattan federal criminal trial. The jury found Bankman-Fried guilty, and a judge sentenced him to 25 years in prison. The federal government took ownership of Singh's and Ellison's Anthropic shares by April 2025.

The US Marshals Service sold Singh's and Ellison's shares, rather than hold on to the red-hot Anthropic stock, Business Insider previously reported. The US Marshals Service Complex Assets Unit is typically tasked with dispensing shares of private companies acquired through criminal forfeiture.

Now we know that Anthropic purchased the stock from the feds in October 2025 at the price of $140.9676 per share, which is the same price Anthropic set for its Series F-1 stock in a fundraising round a month earlier.

Anthropic resold the shares to nine investors at the same $627 million total price it paid to purchase them from the federal government, so it didn't make a profit from the sale, according to the S-1 filing. It's not clear which nine investors purchased the shares originally owned by Singh and Ellison. Representatives for the US Marshals Service didn't immediately respond to a request for comment.

The Anthropic shares owned by Ellison and Singh took a different path than the $500 million in Series B shares owned by Bankman-Fried himself. His shares ended up as part of FTX's bankruptcy estate, which sold them in 2024 to a few dozen buyers for a total of $1.3 billion.

The federal government sent the proceeds from the sale of Ellison's and Singh's shares to the FTX bankruptcy estate, the Justice Department spokesperson said. Bankruptcy court filings show that the Justice Department transferred $638 million to the bankruptcy estate in late 2025.

The money has gone to repaying creditors, including FTX customers and investors who were scammed by the former crypto wunderkind.

Update: October 26, 2026 — This story has been updated to include a comment from the Justice Department.

Correction: October 27, 2026 — The federal government transferred the proceeds of the sale of Caroline Ellison's and Nishad Singh's Anthropic shares to the FTX bankruptcy estate, according to a DOJ spokesperson. An earlier version of this story misstated whether the funds had been transferred.

Read the original article on Business Insider

  •  

The latest K-beauty craze is made from dead Americans' skin. Now it's aiming for the US.

Close-up of a woman's face and neck with a blue-gloved hand holding a syringe. The center of the syringe is cut out and filled with a human skin texture

Getty Images; Alyssa Powell/BI

A hot, new beauty treatment driving tens of millions of dollars in sales around the globe is now aiming for the US market. Its unusual ingredient: skin from dead Americans.

Each year, tens of thousands of Americans donate bodily tissue upon their deaths, generally by checking a box at a motor vehicle department or through an authorization made by a loved one. Over the past few years, tens of millions of dollars' worth of donated skin has traveled from American tissue banks to biotech companies in South Korea, the beauty capital of the world. There, among other uses, it is turned into injectable beauty treatments.

The maker of the market-leading Korean brand said last week it has signed a distribution contract to introduce its skin-derived injection to the US market next year. It isn't clear whether the product can be sold in the US without approval from federal regulators.

Business Insider traced the tissue supply chain to understand how donor tissue from, say, San Antonio can end up for sale at a clinic in Seoul — and how much money is being made along the way.

People who donate tissue "have no idea of how much money is changing hands in the course of all of this," Ana Iltis, a professor at Wake Forest and former president of the American Society for Bioethics and Humanities, told Business Insider. "With tissue donation, there's a lot of money at stake."

Donors and their families can't be paid for organ or tissue donations under US law.

A K-beauty trend

For decades, American plastic surgeons have used products made from human tissue for skin grafts and reconstructive surgeries. That practice includes aesthetic uses — such as cartilage for a nose job or skin for a breast augmentation — though many doctors prefer to use the patient's own tissue for such procedures.

Now, skincare treatments made from human tissue can be purchased for a few hundred dollars and administered at a med spa or dermatology clinic in under an hour. In South Korea, a mecca for cutting-edge beauty treatments, at least 10 biotech companies are making or planning to introduce skin-derived injections.

They are the latest generation of a treatment known among beauty obsessives as "skin boosters." Get your algorithm just right, and your social-media feeds will soon be full of before-and-afters showing off the purported benefits of these products. They depict patients, typically women and sometimes young ones, going from dull to dewy, fine-lined to smooth.

This year, the skin-derived injections are projected to generate $75 million in sales in South Korea, according to analysts at Yuanta Securities.

No brand is bigger than Re2O, which one dermatologist on Instagram called "the Love Potion No. 9 for cells." It accounts for between 60% and 70% of sales in the category, according to L&C Bio, its manufacturer.

A client lies under towels while a practitioner uses a syringe and handheld device during a facial treatment.
South Korea is a mecca for cutting-edge beauty treatments.

JUNG YEON-JE/ Getty Images

Re2O notched the equivalent of more than $17 million in sales in the first half of this year, helping swing the company to an operating profit of about $11 million after a loss of about $326,000 in the same period last year, L&C Bio said. It has expanded the product line with Re2O Fine, marketed for more delicate skin, and is planning to launch a human fat-derived filler next year.

The company said it sold 700,000 units of Re2O as of September. It is available in Singapore and China, and has been approved in the United Arab Emirates, Peru, and Thailand.

Last week, L&C Bio said that it has signed a contract to deliver at least $60 million of Re2O to the US over the next five years. The company also said it may explore acquiring US tissue banks with its US distribution partner.

L&C Bio's plan to introduce Re2O to the US could spark a regulatory showdown. L&C Bio has said Re2O falls into a category of products such as skin grafts that don't require approval from the US Food and Drug Administration.

Some products that manufacturers claim qualify to be sold under this category don't actually meet the applicable criteria, the FDA told Business Insider. The agency said it wouldn't discuss any specific products under investigation.

"Products derived from donor skin that have been decellularized, dried, and ground into a powder for injection as a cosmetic 'skin booster' may raise significant questions" and may have to go through a more complex regulatory approval process, the agency said.

L&C Bio said it wouldn't comment on its discussions with regulators.

Bar chart showing L&C Bio's quarterly revenue rising steadily from 17.7 billion South Korean won in the first quarter of 2025 to 38.8 billion won in the second quarter of 2026.

Re2O's biggest competitor, CellREDM, came onto the South Korean market in late 2025. It has been such a success that in the quarter ended June 30, operating income for its maker, Hans Biomed, soared to over $3 million after barely eking out a profit in the year-earlier period.

The tissue business

"In the human tissue business, access to raw materials is the lifeblood of the industry," L&C Bio's founder and CEO, Whan Chul Lee, said in Korean in a February interview with a South Korean news outlet.

For his company and its competitors, that lifeblood flows from the United States.

Roughly 90% of all the human tissue used in South Korea is imported, according to South Korea's Ministry of Food and Drug Safety. Less than 4% of South Korean adults are registered to donate organs, and even fewer donate tissue. Korean biotech companies have turned primarily to the US, where well over half of adults are registered donors.

Cadaver skin is collected in the US by organ procurement organizations, known as OPOs, and tissue banks. In the transplant system, skin is treated as a tissue, not an organ.

After tissue is collected, its route can vary. A nonprofit OPO often transfers it to an American tissue bank. The tissue bank pays a fee to the OPO, depending on factors like the amount and quality of tissue recovered. The fee covers the cost of the tissue recovery as well as a margin that supports other programs offered by the OPO.

Tissue banks — which can be nonprofit or for-profit entities — supply donor skin to Korean biotech firms.

Much of the US skin supplied to South Korea is used for more traditional medical purposes, like skin grafts for burn victims. L&C Bio makes such therapeutic products and says it prioritizes supply for them.

A person walks in a subway station by ads for plastic surgery.
Tens of millions of dollars' worth of donated skin has traveled over the past few years from American tissue banks to biotech companies in South Korea.

Ed Jones/AFP via Getty Images

L&C Bio spent more than $25 million on donor skin from US tissue banks between 2023 and 2025 and $3.8 million in the first half of this year, according to corporate filings. The company told Business Insider that a quarter of its skin supply is used to make Re2O.

Organ distribution is coordinated by a public-private partnership with the federal government. Tissue is handled differently. It is distributed through commercial relationships.

The more traditional business aspects of the tissue industry have been a subject of debate since the federal law governing America's organ recovery and distribution system was enacted in the 1980s. In a system that relies on altruism, money changing hands could affect public trust, Jerold Mande, who helped write the National Organ Transplant Act, told Business Insider.

There is little data on American attitudes toward tissue donation. A survey of more than 1,000 families of donors in the US published in a 2010 academic journal found less than 30% said they thought it was acceptable for donated tissues to be processed and distributed by for-profit companies.

Revenue from tissue, primarily skin and bone, drove 93% of American OPO profits between 2013 and 2017, or a total of about $107 million per year in profit at 51 OPOs, according to a study in the medical journal Transplantation. The Association of Organ Procurement Organizations called the study outdated, said the money collected for tissue helps fund other life-saving work, and objected to the study's use of the word "profit."

"Reimbursed funds go directly back into the organization, supporting organ procurement as well as aftercare programs for donor families such as bereavement support and grief counseling," said Jenny Daigle, a spokesperson for the Association of Organ Procurement Organizations. Organizations must have a margin and reserves to remain financially stable, she added.

Human tissue donations help millions of people in the US each year, including skin for burn victims, bone for cancer survivors, and eyes for the visually impaired, Daigle said.

Organ donor option in driver license
Tens of thousands of Americans donate bodily tissue each year upon their deaths, often by checking a box at a motor vehicle department.

Patrick Sison/ AP Photo

Regenerative Biologics, a Florida tissue bank, provides all the skin for Re2O, L&C Bio confirmed to Business Insider.

Regenerative's CEO, Sandy McCann, said her tissue bank acts as an intermediary, supplying skin collected by other organizations, and provides L&C Bio only with skin from donors who have given consent for international and cosmetic use. If other American tissue banks have skin that they can't use, "many times we can place it where someone can," she said.

Regenerative had just over $16 million in annual revenue in 2024 and 2025, according to reports filed with a Florida regulator.

By reviewing South Korean government records and images of product packaging, Business Insider identified two other US tissue banks, South Texas Blood and Tissue and RTI Surgical, that supply tissue for skin-derived injectable beauty treatments made by Korean companies.

South Texas Blood & Tissue supplies skin used to make South Korea's No. 2 brand, CellREDM. The tissue bank is based in San Antonio, sometimes called "Military City, USA" because of the large military base there. Educational materials on the tissue bank's website say that donor skin "heals patients suffering from burns or other traumatic wounds, and in reconstructive surgeries, including those wounded during military service."

South Texas Blood & Tissue said each of its tissue donors helps an average of 75 recipients. International distribution and commercial use are longstanding practices in the tissue industry, the group said. Tissue donor families have the option to decline cosmetic, international, or research use, the group added.

"Our top priority is to serve as good stewards of these tissue donations, and to ensure that all tissue we recover has the greatest impact possible," it said.

RTI, a Florida tissue bank that does business as Evergen, said it transfers a small amount of unprocessed donor skin to DOF, a tissue bank in South Korea that manufactures the skin-derived injection product Juveacell. RTI added that it is "dedicated to honoring the generosity of donors and their families."

The Axel Springer Global Reporters Network harnesses the resources of the company's newsrooms to publish ambitious scoops, investigations, interviews, opinion pieces and analysis. It allows journalists — including those from POLITICO, Business Insider, The Telegraph, WELT, BILD, Onet and Fakt — to collaborate on major stories for an international audience of hundreds of millions across platforms: online, print, TV and audio.

Read the original article on Business Insider
  •  

Salesforce has held talks to buy Listen Labs, an AI customer research platform, for around $2 billion

Salesforce CEO Marc Benioff onstage at his company's annual Dreamforce in San Francisco, September, 2024.
Salesforce CEO Marc Benioff speaks to thousands at the Moscone South Hall during Dreamforce in San Francisco on Tuesday, Sept. 17, 2024.

Brontë Wittpenn/San Francisco Chronicle via Getty Images

  • Salesforce has been in talks to acquire AI startup Listen Labs for around $2 billion.
  • Listen Labs, which was last valued at $500 million, sells an AI market analysis platform.
  • Recent AI M&A deals include Nvidia's $12.9 billion acquisition of AI startup Hugging Face.

Salesforce could be on the hunt for acquisitions to beef up its AI capabilities.

The software giant has recently been in talks to buy Listen Labs, an AI-powered customer research platform for around $2 billion, according to people familiar with the matter. The talks have not been finalized and could ultimately be unsuccessful, according to a person with knowledge of the deal.

Salesforce and Listen Labs did not respond to requests for comment.

Listen Labs was founded in 2023 by Alfred Wahlforss and Florian Juengermann, who first met as undergraduates at Harvard University while building an AI avatar app that went viral, attracting 20,000 users on its first day, according to Sequoia Capital. Juengermann was previously a national champion in competitive programming in Germany.

They used an early version of what would become Listen Labs to interview users, which helped them realize that using AI for market research would be extremely valuable.

The company's software automates much of the qualitative research process, which has typically been expensive and time-consuming.

Customers include Microsoft, Anthropic, Google, Nestle, Sweetgreen, and Perplexity. At the beginning of the year, Listen Labs said it had grown its annualized revenue by 15x and interviewed more than one million people in nine months.

For Salesforce, the deal would strengthen its broader quest to make its agentic AI platform, Agentforce, more than just about automating repetitive work. Listen Labs could boost Agentforce by understanding what customers are thinking. It could recommend which products they might buy and craft the perfect pitch for salespeople to close a deal.

If the deal were finalized, it would be part of a wave of AI acquisitions in recent weeks, with Nvidia acquiring HuggingFace for around $12.9 billion and Stripe buying OpenRouter for around $8 billion.

Salesforce has been pushing to improve its AI efforts, with a particular focus on enterprise agents. The Information reported that they considered acquiring HuggingFace before it was sold to Nvidia.

Listen Labs was last valued at $500 million in a financing round earlier this year. Its backers include Sequoia Capital, Ribbit Capital, Conviction Partners, and Pear VC.

Read the original article on Business Insider

  •